Bayer’s Xarelto approved in the UK
First oral factor Xa inhibitor approved for paediatric venous thromboembolism
Read More
Tag: Xarelto
Xarelto success in paediatric venous thromboembolism
The full findings of the study were presented during a late-breaking session at the 27th Congress of the International Society on Thrombosis and Haemostasis.
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
Xarelto approved to cut risk of major CV events in CAD/PAD patients
US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD).
Read More
Bayer, J&J’s Xarelto fails to hit PhIII targets
Bayer and Johnson & Johnson’s plans to expand the scope of blood thinner Xarelto have hit a setback after the drug failed to hit targets in two studies in venous thromboembolism and heart failure studies.
Read More
Bayer, Janssen’s Xarelto cuts risk of amputation, death
Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.
Read More
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Read More
EU OKs low-dose Xarelto to prevent recurrent VTE
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
Read More
Bayer’s Xarelto beats aspirin in preventing blood clots
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.
Read More
Bayer/Janssen’s Xarelto artery disease trial stopped early
Bayer/Janssen’s bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.
Read More
EU to review Portola’s blood-thinner antidote
The group is seeking conditional approval for the drug’s use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
